Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06205602 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06205602 · ClinicalTrials.gov record · last posted 2026-08-17

Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa

Study acronym: ACACIA
StatusActive, Not Recruiting
PhasePhase 2
Started2025-01-17
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
For people living with HIV, antiretroviral therapy (ART) helps to stop the virus from multiplying. The goal of current HIV treatment is to have such a small amount of the virus in the blood that it does not show up on regular tests. HIV is also hidden in cells throughout the body and can start multiplying when ART is stopped. This research study will test two new study drugs: 10-1074-LS and 3BNC117-LS. Both of these study drugs are antibodies against HIV. An antibody is generally a substance that the body makes in response to an infection. The antibodies being used in this study were made in a laboratory and were designed to attach to HIV and can block HIV from attacking cells in the body and from spreading to other parts of the body. These antibodies are being developed to potentially treat and prevent HIV. The main purpose of this study is to see if the study drugs affect the level of HIV that remains in the blood cells while taking ART and the level of HIV in the blood after discontinuing taking ART. The study will also see if it is safe to give people these antibodies and if they cause any side effects.

Protocol amendment history 1 change detected by DataLookout

2026-08-18
notable
Enrollment closed, study ongoing
Trial Details
NCT Number NCT06205602
Lead Sponsor Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions HIV-1-infection
Enrollment 135 participants
Start Date 2025-01-17
Primary Completion 2029-02-16 (estimated)
Study Completion 2029-02-16 (estimated)
Updated on ClinicalTrials.gov 2026-08-17